Remed Co.,Ltd.
Financials
Valuation Metrics
Remed Co.,Ltd.'s Market Cap is ₩742B. At end of 2025 it was ₩929B. Ranked #1473 of 2,410 in KR market (top 61%), #843 of 1,631 on KOSDAQ (top 52%), #54 of 94 in Health Care Equipment & Services (top 57%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 74.17B KRW | KR#1,473/2,410 Sec#54/94 |
| Revenue | 27.05B KRW | KR#2,061/2,410 Sec#68/94 |
| Net Income | 1.25B KRW | KR#1,460/2,410 Sec#45/94 |
| Total Assets | 53.91B KRW | KR#2,171/2,410 Sec#71/94 |
| Net Assets | 39.46B KRW | KR#2,054/2,410 Sec#71/94 |
| Employees | 104 | KR#1,609/2,410 Sec#56/94 |
| Value | ||
| P/E | 59.44x | KR#1,439/2,410 Sec#46/94 |
| P/B | 1.89x | KR#1,909/2,410 Sec#64/94 |
| P/S | 2.75x | KR#1,961/2,410 Sec#62/94 |
| EV/EBITDA | 34.22x | KR#1,239/2,410 Sec#40/94 |
| Profitability | ||
| ROE | 3.18% | KR#1,315/2,410 Sec#43/94 |
| ROA | 2.32% | KR#1,159/2,410 Sec#44/94 |
| Op. Margin | 7.22% | KR#711/2,410 Sec#34/94 |
| Revenue Growth | 10.52% | KR#870/2,410 Sec#45/94 |
| Earnings Growth | -19.42% | KR#927/2,410 Sec#37/94 |
| Financial Health | ||
| Debt Ratio | 36.60% | KR#719/2,410 Sec#34/94 |
| Total Debt | 1.12B KRW | KR#1,939/2,410 Sec#72/94 |
| Cash | 8.47B KRW | KR#1,781/2,410 Sec#58/94 |
| Current Ratio | 2.34x | KR#740/2,410 Sec#43/94 |
| Net Debt/EBITDA | -3.76x | KR#126/2,410 Sec#3/94 |
| Performance | ||
| 1Y Return | -25.45% | KR#1,434/2,410 Sec#46/94 |
| 1M Return | -6.64% | KR#1,543/2,410 Sec#62/94 |
| From 52W High | -39.56% | KR#891/2,410 Sec#34/94 |
| 1Y MDD | -42.82% | KR#668/2,410 Sec#23/94 |
| Trading | ||
| Volume | 117,222 shares | KR#1,093/2,410 Sec#45/94 |
| Trading Value | 278.4M KRW | KR#1,511/2,410 Sec#64/94 |
| Foreign Own. | 0.00% | KR—/2,410 Sec—/94 |
| Per Share | ||
| EPS | 41 KRW | KR#1,511/2,410 Sec#47/94 |
| BPS | 1,304 KRW | KR#2,240/2,410 Sec#84/94 |
Company Info
REMED, established in 2003 and headquartered in Cheongju-si, Chungcheongbuk-do, develops and manufactures non-invasive medical devices that induce nerve cell depolarization using strong magnetic fields. The company operates in brain rehabilitation, chronic pain treatment, and aesthetics, with its neuromodulation device for chronic pain treatment and transcranial magnetic stimulation device for brain rehabilitation having received U.S. FDA approval in 2021. REMED is targeting the global market by entering the U.S. market for TMS for depression treatment, expanding sales internationally, conducting clinical trials for mental illnesses, and premiumizing Peripheral Magnetic Stimulation products.